Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer’s liquid Leukine withdrawn

Executive Summary

Bayer withdraws current liquid formulation of myeloid growth factor Leukine (sargramostim), used to boost immunity in patients undergoing cancer treatment, due to an increase in spontaneous reports of adverse reactions including syncope (fainting). AEs are linked to a change in the formulation of liquid Leukine to include EDTA (edentate disodium). While the firm works to increase supplies of lyophilized Leukine - for which no safety signal was observed - and reformulate the liquid product, it will provide priority access to the lyophilized formulation to oncologists and hematologists who use the drug to treat patients following induction chemotherapy in acute myelogenous leukemia and bone marrow transplantation failure or engraftment delay...

You may also be interested in...



Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

Balancing Innovation And Safety – The US and Australian Medtech Regulatory Systems Compared

Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel